+33 (0)1 76 54 08 64
66 avenue des Champs-Élysées
75008 Paris – France
Proimaging developed a tumor labeling dye for image-guided surgery of cancer tumors.
Fluorescence-guided surgery gives the surgeon the ability to see better and deeper the tumor tissue. This is a non-invasive and very effective way to locate the tumor during surgery and perform a complete removal.
The near-infrared molecule penetrates human tissues and allows the surgeon to see through layers of tissue and organs. During the operation, the surgeon will be able to locate the tumor and its metastases more easily and perform the removal of the entire tumor tissue.
Proimaging is currently working on the development of its lead product CJ215 for the visualization of delineation of cancer tumor in intraoperative fluorescence imaging.
CJ215 is a fluorophore with an affinity to tumoral tissue. It is not linked to an antibody-like molecule, but its effectiveness has been proven for direct use due to its specificity for targeting tumor tissue.
Proimaging evaluated CJ215's ability to target mammary tumors.
CJ215 was evaluated in preclinical in-vivo study on a mouse model grafted with a fluorescent breast tumor line developed by the Imaging & Cytometry Platform (PFIC) of Gustave Roussy Institute.
The tumor-targeting efficiency of CJ215 was quantified by whole-body fluorescence imaging after optimization of injected doses and post-injection delays.
CJ215 has proven to be particularly effective for tumor targeting regardless of the stage of tumor development; early (7 days) or late (21 days post tumor cell transplant). This demonstrates a possible early-stage detection of tumor tissue.
The fluorescence signal is perfectly detectable between 24 and 48 hours after injection of CJ215 and quantitatively from 2 hours after injection.
Imaging at 48h post-injection provided the best tumor/surrounding tissue signal ratio reflecting good retention in tumors and rapid elimination of CJ215 in surrounding tumor tissues and organs in general.
Further study demonstrated 6-day product persistence in tumor tissue significantly improving the signal-to-noise ratio.
Proimaging evaluated CJ215's ability to target pancreatic tumors.
CJ215 was evaluated in preclinical in-vivo study on a murine patient-derived orthotopic pancreatic tumor model developed by Oncodesign.
Study showed presence of CJ215 in pancreas and tumor at 2h. Persistence of signal in the tumor at 48h. Good contrast between tumor and pancreas.
Ex-vivo imaging after 2h showed that CJ215 was present in the pancreas and tumor. A preferential distribution for the tumor was observed, with a four-fold higher fluorescent signal in the tumor than in the surround pancreatic tissue.
Preferential pancreatic tumor distribution of CJ215 is observed and persisted six days after injection.